drugset
drugset / Trial / NCT00297817

Study of the Safety and Immune Response of Two Serogroup B Meningococcal Vaccines Administered to Healthy Adolescents

NCT00297817 ↗

Phase 2 Completed 203 enrolled Novartis Vaccines
RandomizedParallel-groupSingle-blindPrevention

Summary

The purpose of this study is to evaluate the safety and immunogenicity of two serogroup B meningococcal vaccines in comparison to placebo administered to healthy adolescents ages 11 to 18 years.

Timeline

Start
2006-02
Primary completion
2007-04
Completion
2007-04

Drugs

EvaluationDrugModalityDoseRoute
Comparator serogroup B meningococcal vaccine Vaccine 0.5 ml —

Indications

meningococcal infection